1. ALLA AKTIER
  2. NYHETER
  3. ONCOPEPTIDES

Oncopeptides

Nyheter Oncopeptides Nyheter alla bolag

Number of shares and votes in Oncopeptides

LHFI

STOCKHOLM — September 29, 2023 — Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the number of shares and votes in Oncopeptides has changed due to exercise of warrants under the company´s incentive program. Through the exercise of the warrants the number of outstanding shares and votes has increased by 70,967 from 94,529,110 to 94,600,077. The share capital has increased with SEK 7,886 from SEK 10,503,235 to SEK 10,511,120.

As of today, the total number of outstanding shares in Oncopeptides amounts to 94,600,077 shares, of which 90,439,627 are ordinary shares and 4,160,450 are class C shares. The number of votes in Oncopeptides as of today amounts to 90,855,672.

For more information, please contact:
David Augustsson, Director of Corporate Affairs, Oncopeptides AB (publ)
E-mail: david.augustsson@oncopeptides.com
Cell phone: +46 76 229 38 68

This information is information that Oncopeptides is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-09-29 08:00 CEST.

About Oncopeptides
Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. 

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com. 

Attachments
Number of shares and votes in Oncopeptides

Datum 2023-09-29, kl 08:00
Källa MFN
Bifogade filer
Number of shares and votes in Oncopeptides
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!